Overview

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Status:
Completed

Trial end date:
2017-10-23

Target enrollment:

Participant gender:

Summary

The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Albumin-Bound Paclitaxel
Everolimus
Paclitaxel
Sirolimus
Trastuzumab